0001562180-22-007012.txt : 20221004
0001562180-22-007012.hdr.sgml : 20221004
20221004174919
ACCESSION NUMBER: 0001562180-22-007012
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220930
FILED AS OF DATE: 20221004
DATE AS OF CHANGE: 20221004
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Metzger Michael A
CENTRAL INDEX KEY: 0001507220
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37708
FILM NUMBER: 221293420
MAIL ADDRESS:
STREET 1: C/O SYNDAX PHARMACEUTICALS, INC.
STREET 2: 400 TOTTEN POND ROAD,
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Syndax Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001395937
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 320162505
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
STREET 2: BUILDING D, FLOOR 3
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-419-1400
MAIL ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
STREET 2: BUILDING D, FLOOR 3
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2022-09-30
false
0001395937
Syndax Pharmaceuticals Inc
SNDX
0001507220
Metzger Michael A
C/O SYNDAX PHARMACEUTICALS, INC.
35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3
WALTHAM
MA
02451
true
true
false
false
Chief Executive Officer
Common Stock
2022-09-30
4
M
false
29606.00
8.77
A
47265.00
D
Common Stock
2022-09-30
4
S
false
29606.00
25.0205
D
17659.00
D
Common Stock
2022-10-03
4
M
false
2883.00
8.77
A
20542.00
D
Common Stock
2022-10-03
4
S
false
2883.00
25.011
D
17659.00
D
Common Stock
2022-10-04
4
M
false
1280.00
8.77
A
18939.00
D
Common Stock
2022-10-04
4
S
false
1280.00
25.0206
D
17659.00
D
Stock Options (Right to buy)
8.77
2022-09-30
4
M
false
29606.00
0.00
D
2027-02-06
Common Stock
29606.00
0.00
D
Stock Options (Right to buy)
8.77
2022-10-03
4
M
false
2883.00
0.00
D
2027-02-06
Common Stock
2883.00
0.00
D
Stock Options (Right to buy)
8.77
2022-10-04
4
M
false
1280.00
0.00
D
2027-02-06
Common Stock
1280.00
0.00
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 690,759 options to purchase shares of common stock that are vested and immediately exercisable and a total of 485,001 options to purchase shares of common stock that have not yet vested.
The sale prices ranged from $25.00 to $25.15.
The sale prices ranged from $25.00 to $25.03.
This option is fully vested.
/s/ Michael A. Metzger
2022-10-04